Genedrive Share Discussion Threads

[purple11] 11/8/2024 08:59

YOULL SEE

512p £16.52P

[purple11] 11/8/2024 08:51

LETS ALL BUY GEX GL

[divmad] 11/8/2024 08:45

How do you know he is underwater, yet alone heavily?

[purple11] 11/8/2024 08:11

rubbish.theyve been spouting those lines for 16 years. atb

[z1co] 11/8/2024 07:55

For purple11 also known as runawaypaul who is rather SHORT SIGHTED and can't the HUGE potential for the business going forward:

The Company estimates that the total world wide market for CYP2C19-ID Kit is worth more than £200m per annum.

With the UK market alone worth up to £8.5 million per annum, based on the assumption that there are over 100,000 strokes per annum and an estimated customer price per test of approximately £100. The EU market is estimated to be c.£93.5 million, the U.S. market is c.£67.6 million and rest of the world markets approximately £51 million. Market estimates are based on end user pricing.

[purple11] 11/8/2024 07:29

£100k per year ReveNue

SELL

[z1co] 11/8/2024 07:19

The new CEO's recent comments:

Our positioning in near-patient pharmacogenetic testing in emergency care paradigms is exemplified by our two leading products; our MT-RNR1 ID Kit for avoidance of antibiotic induced hearing loss in neonatal intensive care settings, and our CYP2C19 ID kit primarily aimed at pre-emptive stratification of those individuals presenting with stroke that are less likely to respond to the commonly prescribed antiplatelet Clopidogrel.

Both interventional products have been recognised & recommended by the UK National Institute for Clinical Care and Excellence for use in the UK NHS, offering significant potential monetary savings to healthcare systems and significantly better health outcomes for patients.

I am thrilled to be leading the fantastic team at genedrive into our next phase of development; growth and commercialisation, and ultimately providing positive benefits to patients worldwide.


The collaboration of our company with the research and clinical team at MFT is a shining example of the NHS collaborating with a commercial company, from early product development through to clinical validation in real-world settings, to deliver real improvements in patient outcomes in a cost-effective way. We are delighted with the positive recommendation from NICE and the success of the multi-disciplinary team collaboration under DEVOTE. We look forward to our CYP2C19 ID kit, the second point of care pharmacogenetic test developed in collaboration with this team for NHS use, being made available for the benefit of patients who have suffered a stroke or TIA.

[z1co] 11/8/2024 07:14

This was my post yesterday:

The company has TWO world class products approved by NICE and at some point in the future will get FDA clearance to sell in the US.

The company has invested more than £40m over the last decade or so in developing the genedrive platform and getting these TWO products approved.

Getting a medical product approved takes a lot of time and money.

Valued at just £18m are vulnerable to a BID and could easily be bought out by a larger pharma/bio company for their world class products.

IF SOME ONE DOES DECIDE TO BUY THE COMPANY IT WILL BE NORTH OF £100m ie IN EXCESS OF 20P

[z1co] 11/8/2024 07:13

Great post by Stockriser

Stockriser11 Aug '24 - 00:28 - 7749 of 7754
0 2 0
Apologies if already posted - thanks to Lionlel1 (on LSE BB) for link to article - this company is now primed for a takeover with a bid far in excess of todays Mcap. I feel the birth of a multi-bagger. ;-)

Manchester leads implementation of lifesaving genetic bedside stroke test

“If adopted into routine practice, this rapid test, which has been recommended for use in the NHS by the National Institute for Health and Care Excellence (NICE), represents a major transformation in the way we manage stroke in this country."

“Our early model-based cost-effectiveness analysis published last year shows that using a rapid genetic test could lead to significant cost savings for the NHS. Using a rapid genetic test was £512 less expensive compared with no testing per patient, due to the prevention of secondary strokes and reduced hospital admissions. When you factor in the potential improvements in a patients’ quality of life, the model estimates that the potential saving to the NHS is over £160 million each year.”



GLA SR

[purple11] 11/8/2024 04:21

£100k per year revenue

[premium beeks] 11/8/2024 02:23

How do you correlate that with "primed for takeover"? It's no more primed for takeover than any other company on the exchange with a "product".It's already well valued for the revenue / profit it makes. But nice ramp.

[stockriser] 10/8/2024 23:28

Apologies if already posted - thanks to Lionlel1 (on LSE BB) for link to article - this company is now primed for a takeover with a bid far in excess of todays Mcap. I feel the birth of a multi-bagger. ;-)

Manchester leads implementation of lifesaving genetic bedside stroke test

“If adopted into routine practice, this rapid test, which has been recommended for use in the NHS by the National Institute for Health and Care Excellence (NICE), represents a major transformation in the way we manage stroke in this country."

“Our early model-based cost-effectiveness analysis published last year shows that using a rapid genetic test could lead to significant cost savings for the NHS. Using a rapid genetic test was £512 less expensive compared with no testing per patient, due to the prevention of secondary strokes and reduced hospital admissions. When you factor in the potential improvements in a patients’ quality of life, the model estimates that the potential saving to the NHS is over £160 million each year.”



GLA SR